TC BioPharm (Holdings) plc Warrants
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat … Read more
TC BioPharm (Holdings) plc Warrants (TCBPW) - Total Liabilities
Latest total liabilities as of September 2024: $4.87 Million USD
Based on the latest financial reports, TC BioPharm (Holdings) plc Warrants (TCBPW) has total liabilities worth $4.87 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TC BioPharm (Holdings) plc Warrants - Total Liabilities Trend (2019–2023)
This chart illustrates how TC BioPharm (Holdings) plc Warrants's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TC BioPharm (Holdings) plc Warrants Competitors by Total Liabilities
The table below lists competitors of TC BioPharm (Holdings) plc Warrants ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GDO
F:GDO
|
Germany | €310.33K |
|
AKER -A-
BE:FKM
|
Germany | €37.96 Billion |
|
LSEB Creative Corp.
OTCQB:LSEB
|
USA | $202.60K |
|
AMADEUS IT HOLD -A-
BE:AI3A
|
Germany | €6.74 Billion |
|
Stone Gold Inc.
PINK:STGDF
|
USA | $224.58K |
|
ARCHER-DANIELS MID.
MU:ADM
|
Germany | €30.24 Billion |
|
Bravo Multinational Inc
PINK:BRVO
|
USA | $1.00 Million |
Liability Composition Analysis (2019–2023)
This chart breaks down TC BioPharm (Holdings) plc Warrants's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TC BioPharm (Holdings) plc Warrants's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TC BioPharm (Holdings) plc Warrants (2019–2023)
The table below shows the annual total liabilities of TC BioPharm (Holdings) plc Warrants from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $6.25 Million | -43.01% |
| 2022-12-31 | $10.96 Million | -55.41% |
| 2021-12-31 | $24.58 Million | +131.61% |
| 2020-12-31 | $10.61 Million | -16.29% |
| 2019-12-31 | $12.68 Million | -- |